The pharmacology of novel TMEM16A potentiator compounds Henry Danahay1,2, Sarah Lilley1, Holly Charlton1, Roy Fox1, Brian Button3, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK; 3University of North Carolina, Chapel Hill, USA TMEM16A was recently identified as a calcium-activated chloride conductance and a key orchestrator of anion secretion in the human airway epithelium […]
EACT increases intracellular calcium levels by a TMEM16A-independent mechanism Sarah Lilley1, Henry Danahay1,2, Holly Charlton1, Kathryn Adley1, Roy Fox1, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK The N-aroylaminothiazole EACT was first described by Namkung et al. (2011) as an activator of the calcium-activated chloride channel, TMEM16A. Subsequently, EACT has been used as […]
Appointment brings significant commercial pharma experience as Enterprise Therapeutics’ two lead respiratory programmes are progressed towards the clinic Brighton, UK, 25 March 2019: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the appointment of Amit […]
Identifying pathways & compounds regulating goblet cell metaplasia in vitro Henry Danahay1, Roy Fox2 and Martin Gosling1 1Enterprise Therapeutics, UK; 2University of Sussex, UK It is widely accepted that the composition of mucus in the CF airway, and the hydration status, significantly affects its clearance and thereby the potential for form plugs, restrict airflow and […]
Scrip Awards 2018 “Financing Deal of the Year- Private” category Lifestars Awards 2018 “EU Private Finance Raise of the Year <£30M” category Brighton, UK – 02 October 2018: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, has recently been announced as […]
Submission: 210 – PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE OF A NOVEL INHALED ENAC BLOCKER, ETD001 Henry Danahay1, Clive McCarthy1, William Abraham2, Holly Charlton3, Sarah Lilley3, Roy Fox3 and Martin Gosling1 1Enterprise Therapeutics, UK; 2Mount Sinai Medical Center, USA; 3University of Sussex, UK Inhaled drugs are typically cleared very rapidly from the airway mucosa. Inhaled […]
Submission: 89 – IDENTIFYING PATHWAYS REGULATING GOBLET CELL METAPLASIA: PHENOTYPIC SCREENING WITH BRONCHOSPHERES Henry Danahay1, Clive McCarthy1, Roy Fox2 and Martin Gosling1 1Enterprise Therapeutics, UK; 2University of Sussex, UK The composition of mucus in the CF airway, and in particular the hydration status, significantly affects its clearance and thereby the potential for form plugs, […]
Brighton, UK – 12 April 2018: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has closed an oversubscribed £29 million ($41 million USD) Series B round co-led by Versant Ventures and Novartis Venture Fund. The syndicate also […]
Inhaled drugs are typically cleared very rapidly from the airway mucosa. Inhaled amiloride, accelerated mucociliary clearance in clinical studies, but with a half-life in the airway mucosa of <30 min, it was a short acting effect which did not translate into clinical efficacy. To achieve a long duration of action in the clinic with novel […]
It is widely accepted that the composition of mucus in the CF airway, and in particular the hydration status, significantly affects its clearance and thereby the potential for form plugs, restrict airflow and create a nidus for chronic microbial colonisation. A variety of largely ion channel-based strategies are being employed to promote mucosal hydration e.g. […]
Sussex Innovation Centre,
University of Sussex,
Science Park Square,
Falmer, Brighton, BN1 9SB
info@enterprisetherapeutics.com
+44 (0)1273 234667
